Analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will announce earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks. Two analysts have made estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.40) to ($0.34). TG Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which would indicate a positive year-over-year growth rate of 14%. The firm is scheduled to announce its next quarterly earnings report on Friday, November 8th.
According to Zacks, analysts expect that TG Therapeutics will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.64) to ($1.30). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.60) to ($0.87). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.01. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 415.54% and a negative net margin of 94,751.79%.
Several analysts recently issued reports on TGTX shares. ValuEngine upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price objective on shares of TG Therapeutics in a report on Monday, May 13th. B. Riley reiterated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, June 11th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $14.07.
Shares of NASDAQ:TGTX opened at $6.55 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 1.89. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $12.90. The business has a fifty day simple moving average of $7.71 and a 200 day simple moving average of $7.06.
In other TG Therapeutics news, CEO Michael S. Weiss bought 50,000 shares of the stock in a transaction on Wednesday, June 26th. The shares were purchased at an average cost of $7.04 per share, with a total value of $352,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean A. Power sold 17,654 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The disclosure for this sale can be found here. 14.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of TGTX. Camber Capital Management LP acquired a new position in TG Therapeutics during the second quarter worth $8,650,000. Sofinnova Investments Inc. increased its position in TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock worth $10,911,000 after buying an additional 909,573 shares during the last quarter. BlackRock Inc. increased its position in TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock worth $45,883,000 after buying an additional 866,572 shares during the last quarter. Vanguard Group Inc. increased its position in TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock worth $34,955,000 after buying an additional 665,380 shares during the last quarter. Finally, Deutsche Bank AG increased its position in TG Therapeutics by 72.2% during the fourth quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock worth $3,378,000 after buying an additional 345,477 shares during the last quarter. 54.48% of the stock is currently owned by hedge funds and other institutional investors.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
See Also: Penny Stocks, What You Need To Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.